New myeloma treatment provides all-oral regimen option

Ninlaro (ixazomib) is the first proteasome inhibitor to be administered orally.

Taken once weekly in combination with a regimen of lenalidomide and dexamethasone, Ninlaro is indicated in patients with multiple myeloma who have received at least one prior therapy.

In a randomised, double-blind, placebo-controlled pivotal trial in 722 patients with relapsed and/or refractory multiple myeloma, addition of ixazomib to treatment with lenalidomide and dexamethasone was associated with a 40% increase in progression-free survival.

Median progression-free survival was 20.6 months in patients receiving ixazomib plus lenalidomide/dexamethasone compared with 14.7 months in those given placebo plus lenalidomide/dexamethasone (hazard ratio for disease progression or death in the ixazomib group, 0.74; p=0.01).

The rates of serious adverse events, discontinuation due to adverse events, and death during the study period were similar in the two groups.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more